Democrats who handed the Schumer-Manchin invoice on Sunday voted to lift drug prices and well being premiums for 220 million privately insured People. That isn’t hyperbole. It’s the inevitable financial results of Medicare drug value controls after the Senate parliamentarian this weekend struck the invoice’s inflation rebates.
Democrats know their Medicare take-it-or-leave-it drug “negotiations”—i.e., value controls—may have spill-over results on the industrial market. This was one argument they made to the Senate parliamentarian for retaining the invoice’s requirement that drug makers pay Medicare rebates in the event that they elevate costs within the industrial market increased than inflation.
